295 related articles for article (PubMed ID: 31924225)
1. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
2. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
3. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
4. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
6. Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis.
Shimizu M; Mizuta M; Yasumi T; Iwata N; Okura Y; Kinjo N; Umebayashi H; Kubota T; Nakagishi Y; Nishimura K; Yashiro M; Yasumura J; Yamazaki K; Wakiguchi H; Okamoto N; Mori M
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1412-1415. PubMed ID: 29195002
[TBL] [Abstract][Full Text] [Related]
7. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Ravelli A; Minoia F; Davì S; Horne A; Bovis F; Pistorio A; Aricò M; Avcin T; Behrens EM; De Benedetti F; Filipovic L; Grom AA; Henter JI; Ilowite NT; Jordan MB; Khubchandani R; Kitoh T; Lehmberg K; Lovell DJ; Miettunen P; Nichols KE; Ozen S; Pachlopnik Schmid J; Ramanan AV; Russo R; Schneider R; Sterba G; Uziel Y; Wallace C; Wouters C; Wulffraat N; Demirkaya E; Brunner HI; Martini A; Ruperto N; Cron RQ; ; ; ;
Ann Rheum Dis; 2016 Mar; 75(3):481-9. PubMed ID: 26865703
[TBL] [Abstract][Full Text] [Related]
8. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Ravelli A; Minoia F; Davì S; Horne A; Bovis F; Pistorio A; Aricò M; Avcin T; Behrens EM; De Benedetti F; Filipovic L; Grom AA; Henter JI; Ilowite NT; Jordan MB; Khubchandani R; Kitoh T; Lehmberg K; Lovell DJ; Miettunen P; Nichols KE; Ozen S; Pachlopnik Schmid J; Ramanan AV; Russo R; Schneider R; Sterba G; Uziel Y; Wallace C; Wouters C; Wulffraat N; Demirkaya E; Brunner HI; Martini A; Ruperto N; Cron RQ; ; ; ;
Arthritis Rheumatol; 2016 Mar; 68(3):566-76. PubMed ID: 26314788
[TBL] [Abstract][Full Text] [Related]
9. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
Minoia F; Davì S; Horne A; Demirkaya E; Bovis F; Li C; Lehmberg K; Weitzman S; Insalaco A; Wouters C; Shenoi S; Espada G; Ozen S; Anton J; Khubchandani R; Russo R; Pal P; Kasapcopur O; Miettunen P; Maritsi D; Merino R; Shakoory B; Alessio M; Chasnyk V; Sanner H; Gao YJ; Huasong Z; Kitoh T; Avcin T; Fischbach M; Frosch M; Grom A; Huber A; Jelusic M; Sawhney S; Uziel Y; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
Arthritis Rheumatol; 2014 Nov; 66(11):3160-9. PubMed ID: 25077692
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.
Shimizu M; Nakagishi Y; Kasai K; Yamasaki Y; Miyoshi M; Takei S; Yachie A
Cytokine; 2012 May; 58(2):287-94. PubMed ID: 22398373
[TBL] [Abstract][Full Text] [Related]
13. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Davì S; Minoia F; Pistorio A; Horne A; Consolaro A; Rosina S; Bovis F; Cimaz R; Gamir ML; Ilowite NT; Kone-Paut I; Feitosa de Oliveira SK; McCurdy D; Silva CA; Sztajnbok F; Tsitsami E; Unsal E; Weiss JE; Wulffraat N; Abinun M; Aggarwal A; Apaz MT; Astigarraga I; Corona F; Cuttica R; D'Angelo G; Eisenstein EM; Hashad S; Lepore L; Mulaosmanovic V; Nielsen S; Prahalad S; Rigante D; Stanevicha V; Sterba G; Susic G; Takei S; Trauzeddel R; Zletni M; Ruperto N; Martini A; Cron RQ; Ravelli A;
Arthritis Rheumatol; 2014 Oct; 66(10):2871-80. PubMed ID: 25044674
[TBL] [Abstract][Full Text] [Related]
14. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
15. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
[TBL] [Abstract][Full Text] [Related]
16. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis.
Bennett TD; Fluchel M; Hersh AO; Hayward KN; Hersh AL; Brogan TV; Srivastava R; Stone BL; Korgenski EK; Mundorff MB; Casper TC; Bratton SL
Arthritis Rheum; 2012 Dec; 64(12):4135-42. PubMed ID: 22886474
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
18. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
20. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
